0000886163-16-000130.txt : 20160122
0000886163-16-000130.hdr.sgml : 20160122
20160122192430
ACCESSION NUMBER: 0000886163-16-000130
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160120
FILED AS OF DATE: 20160122
DATE AS OF CHANGE: 20160122
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KOZARICH JOHN W
CENTRAL INDEX KEY: 0001223000
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 161357261
MAIL ADDRESS:
STREET 1: 10275 SCIENCE CENTER DR
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2016-01-20
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001223000
KOZARICH JOHN W
11119 NORTH TORREY PINES ROAD, SUITE 200
LA JOLLA
CA
92037
1
0
0
0
Common Stock
2016-01-20
4
M
0
1666.0
59.4
A
51377
D
Common Stock
2016-01-20
4
S
0
300.0
92.71
D
51077
D
Common Stock
2016-01-20
4
S
0
600.0
93.83
D
50477
D
Common Stock
2016-01-20
4
S
0
200.0
94.71
D
50277
D
Common Stock
2016-01-20
4
S
0
200.0
96.28
D
50077
D
Common Stock
2016-01-20
4
S
0
366.0
97.99
D
49711
D
Non-Qualified Stock Option (right to buy)
59.4
2016-01-20
2016-01-20
4
M
0
1666.0
0.0
D
2016-01-31
Common Stock
1666
0
D
The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01,2015, in accordance with Rule 10b5-1.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.24 to $93.24, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.34 to $94.32, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.51 to $94.91, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.23 to $96.33, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.68 to $98.18, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The option becomes exercisable in twelve successive equal monthly installments upon completion of each calendar month of service beginning 1/31/06.
By: Charles S. Berkman For: John W. Kozarich
2016-01-22